Article
A top AstraZeneca exec shares the $200 billion pharma giant's gene-editing ambitions and the timeline to starting human testing
Rating:
0.0
Views:
39
Likes:
1
Library:
1
The pharma giant wants to repair genes with its own technology as a way to cure diseases, AstraZeneca's Steve Rees told Insider.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value